Evidence map›Paper›PMID 25852219›Full record

ArticleDisease markers2015

Vascular effects of advanced glycation end-products: content of immunohistochemically detected AGEs in radial artery samples as a predictor for arterial calcification and cardiovascular risk in asymptomatic patients with chronic kidney disease.

Katarzyna Janda, Marcin Krzanowski, Mariusz Gajda, Paulina Dumnicka, Ewa Jasek, Danuta Fedak, Agata Pietrzycka, Marek Kuźniewski, Jan A Litwin, Władysław Sułowicz

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Similarities and Differences of Vascular Calcification in Diabetes and Chronic Kidney Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Katarzyna JandaChair and Department of Nephrology, Jagiellonian University Medical College, Cracow, Poland.
Marcin KrzanowskiChair and Department of Nephrology, Jagiellonian University Medical College, Cracow, Poland.
Mariusz GajdaChair and Department of Histology, Jagiellonian University Medical College, Cracow, Poland.ORCID 0000-0002-3788-7528
Paulina DumnickaDepartment of Medical Diagnostics, Jagiellonian University Medical College, Cracow, Poland.
Ewa JasekChair and Department of Histology, Jagiellonian University Medical College, Cracow, Poland.
Danuta FedakChair of Clinical Biochemistry, Jagiellonian University Medical College, Cracow, Poland.
Agata PietrzyckaPharmacobiology Department of Pharmacy, Jagiellonian University Medical College, Cracow, Poland.
Marek KuźniewskiChair and Department of Nephrology, Jagiellonian University Medical College, Cracow, Poland.
Jan A LitwinChair and Department of Histology, Jagiellonian University Medical College, Cracow, Poland.
Władysław SułowiczChair and Department of Nephrology, Jagiellonian University Medical College, Cracow, Poland.
Jagiellonian University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesOur aim was to determine whether vascular deposition of advanced glycation end-products (AGEs) is associated with arterial calcification and cardiovascular mortality in chronic kidney disease (CKD) patients and to assess the relationships between vascular content of AGEs and selected clinical and biochemical parameters. MATERIALS AND

methodsThe study comprised 54 CKD patients (33 hemodialyzed, 21 predialyzed). Examined parameters included BMI, incidence of diabetes, plasma fasting glucose, AGEs, soluble receptor for AGEs and 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging, serum C-reactive protein (hsCRP), plasminogen activator inhibitor-1 (PAI-1), and fetuin-A. Fragments of radial artery obtained during creation of hemodialysis access were stained for calcifications using alizarin red. AGEs deposits were identified immunohistochemically and their relative content was quantified.

resultsVascular content of AGEs was positively correlated with BMI, hsCRP, fetuin-A, PAI-1, and DPPH scavenging in simple regression; only fetuin-A was an independent predictor in multiple regression. There was a significant positive trend in the intensity of AGEs immunostaining among patients with grades 1, 2, and 3 calcifications. AGEs immunostaining intensity predicted 3-year cardiovascular mortality irrespective of patient's age.

conclusionsThe present study demonstrates an involvement of AGEs in the development of medial arterial calcification and the impact of arterial AGE deposition on cardiovascular mortality in CKD patients.

Indexed as

Agedalpha-2-HS-GlycoproteinBiomarkersBiphenyl CompoundsCalcinosisCardiovascular DiseasesC-Reactive ProteinFemaleGlycation End Products, AdvancedHumansMaleMiddle AgedPicratesPlasminogen Activator Inhibitor 1Radial ArteryRenal Insufficiency, Chronic1,1-diphenyl-2-picrylhydrazylalpha-2-HS-GlycoproteinBiomarkersBiphenyl CompoundsC-Reactive ProteinGlycation End Products, AdvancedPicratesPlasminogen Activator Inhibitor 1

Identifiers

PMID25852219
PMCPMC4380091
OpenAlexW2073892260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.